Article
Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.
Future oncology (London, England) - 1 Apr 2022
Zhao Jun, Bai Hua, Wang Xin, Wang Yuyan, Duan Jianchun, Chen Hanxiao, Xue Zhiyi, Tian Yahui, Cseh Agnieszka, Huang Dennis Chin-Lun, Wu Yi-Long, Wang Jie
Abstract excerpt
Aim: To explore the relationship between mutations in cfDNA and response to afatinib. Patients & methods: In total, 64 patients from one Chinese site with locally advanced/metastatic EGFRm+ non-small-cell lung cancer, who received afatinib 40 mg once daily, were included. Results: Overall, 33 (82.5%) patients became EGFRm- by visit 3; median progression-free survival was longer in these patients vs those who did...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.